Controlled Substances: Final Revised Aggregate Production Quotas for 2007, 48686-48689 [E7-16730]
Download as PDF
48686
Federal Register / Vol. 72, No. 164 / Friday, August 24, 2007 / Notices
This action meets the applicable
standards set forth in sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by state, local, and tribal
governments, in the aggregate, or by the
private sector, of $120,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
companies to compete with foreignbased companies in domestic and
export markets.
August 15, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–16729 Filed 8–23–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–290F]
Controlled Substances: Final Revised
Aggregate Production Quotas for 2007
Drug Enforcement
Administration (DEA), Justice.
ACTION: Notice of final aggregate
production quotas for 2007.
AGENCY:
yshivers on PROD1PC66 with NOTICES
SUMMARY: This notice establishes final
2007 aggregate production quotas for
controlled substances in schedules I and
II of the Controlled Substances Act
(CSA). The DEA has taken into
consideration comments received in
response to a notice of the proposed
revised aggregate production quotas for
2007 published May 3, 2007 (72 FR
24608).
EFFECTIVE DATE: August 24, 2007.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, PhD, Chief, Drug
and Chemical Evaluation Section, Drug
Enforcement Administration,
Washington, DC 20537, Telephone:
(202) 307–7183.
SUPPLEMENTARY INFORMATION: Section
306 of the CSA (21 U.S.C. 826) requires
that the Attorney General establish
aggregate production quotas for each
basic class of controlled substance listed
in schedules I and II. This responsibility
has been delegated to the Administrator
of the DEA by 28 CFR 0.100. The
Administrator, in turn, has redelegated
this function to the Deputy
Administrator, pursuant to 28 CFR
0.104.
The 2007 aggregate production quotas
represent those quantities of controlled
substances in schedules I and II that
may be produced in the United States in
2007 to provide adequate supplies of
each substance for: the estimated
medical, scientific, research and
industrial needs of the United States;
lawful export requirements; and the
establishment and maintenance of
reserve stocks (21 U.S.C. 826(a) and 21
CFR 1303.11). These quotas do not
include imports of controlled
substances.
On May 3, 2007, a notice of the
proposed revised 2007 aggregate
production quotas for certain controlled
substances in schedules I and II was
published in the Federal Register (72
FR 24608). All interested persons were
invited to comment on or object to these
proposed aggregate production quotas
on or before May 24, 2007.
Nine companies commented on a total
of 31 schedules I and II controlled
substances within the published
comment period. Nine companies
proposed that the aggregate production
quotas for 14-hydroxymorphinone,
alfentanil, amphetamine (for sale),
amphetamine (for conversion), cocaine,
codeine (for conversion),
dextropropoxyphene, dihydromorphine,
diphenoxylate, ecgonine, fentanyl,
gamma hydroxybutyric acid,
hydrocodone, hydromorphone,
lisdexamfetamine, meperidine,
methadone, methadone intermediate,
methylphenidate, morphine, morphine
(for conversion), nabilone,
noroxymorphone (for conversion),
oxycodone, oxymorphone,
oxymorphone (for conversion),
pentobarbital, remifentanil, sufentanil,
tetrahydrocannabinols, and thebaine
were insufficient to provide for the
estimated medical, scientific, research,
and industrial needs of the United
States, for export requirements and for
the establishment and maintenance of
reserve stocks.
The DEA has determined that the
compound 14-hydroxymorphinone is a
morphine derivative. The comment
received concerning this substance was
therefore, considered as a comment for
morphine.
DEA has taken into consideration the
above comments along with the relevant
2006 year-end inventories, initial 2007
manufacturing quotas, 2007 export
requirements, actual and projected 2007
sales, research, product development
requirements and additional
applications received. Based on this
information, the DEA has adjusted the
final 2007 aggregate production quotas
for 2,5-dimethoxyamphetamine,
alfentanil, amphetamine (for
conversion), gamma-hydroxybutyric
acid, hydrocodone, methylphenidate,
oxycodone, oxycodone (for conversion),
pentobarbital, remifentanil, sufentanil
and thebaine to meet the legitimate
needs of the United States.
Regarding amphetamine (for sale),
cocaine, codeine (for conversion),
dextropropoxyphene, dihydromorphine,
diphenoxylate, ecgonine, fentanyl,
hydromorphone, lisdexamfetamine,
meperidine, methadone, methadone
intermediate, morphine, morphine (for
conversion), nabilone, noroxymorphone
(for conversion), oxymorphone,
oxymorphone (for conversion), and
tetrahydrocannabinols the DEA has
determined that the proposed revised
2007 aggregate production quotas are
sufficient to meet the current 2007
estimated medical, scientific, research,
and industrial needs of the United
States and to provide for adequate
inventories.
Therefore, under the authority vested
in the Attorney General by section 306
of the CSA (21 U.S.C. 826), and
delegated to the Administrator of the
DEA by 28 CFR 0.100, and redelegated
to the Deputy Administrator, pursuant
to 28 CFR 0.104, the Deputy
Administrator hereby orders that the
2007 final aggregate production quotas
for the following controlled substances,
expressed in grams of anhydrous acid or
base, be established as follows:
Final revised
2007 quotas
(grams)
Basic class—Schedule I
2,5-Dimethoxyamphetamine ............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ..................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) ................................................................................................................
VerDate Aug<31>2005
14:35 Aug 23, 2007
Jkt 211001
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
E:\FR\FM\24AUN1.SGM
24AUN1
2
2
10
Federal Register / Vol. 72, No. 164 / Friday, August 24, 2007 / Notices
Final revised
2007 quotas
(grams)
Basic class—Schedule I
yshivers on PROD1PC66 with NOTICES
3-Methylfentanyl ...............................................................................................................................................................................
3-Methylthiofentanyl .........................................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ........................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .........................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .............................................................................................................................
3,4,5-Trimethoxyamphetamine ........................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ..................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ..............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................................
4-Methylaminorex ............................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ..................................................................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine ..................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..............................................................................................................................................
Acetyl-alpha-methylfentanyl .............................................................................................................................................................
Acetyldihydrocodeine .......................................................................................................................................................................
Acetylmethadol ................................................................................................................................................................................
Allylprodine ......................................................................................................................................................................................
Alphacetylmethadol ..........................................................................................................................................................................
Alpha-ethyltryptamine ......................................................................................................................................................................
Alphameprodine ...............................................................................................................................................................................
Alphamethadol .................................................................................................................................................................................
Alpha-methylfentanyl .......................................................................................................................................................................
Alpha-methylthiofentanyl ..................................................................................................................................................................
Alpha-methyltryptamine ...................................................................................................................................................................
Aminorex ..........................................................................................................................................................................................
Benzylmorphine ...............................................................................................................................................................................
Betacetylmethadol ...........................................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ........................................................................................................................................................
Beta-hydroxyfentanyl .......................................................................................................................................................................
Betameprodine .................................................................................................................................................................................
Betamethadol ...................................................................................................................................................................................
Betaprodine ......................................................................................................................................................................................
Bufotenine ........................................................................................................................................................................................
Cathinone .........................................................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................................
Diethyltryptamine .............................................................................................................................................................................
Difenoxin ..........................................................................................................................................................................................
Dihydromorphine ..............................................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................................
Gamma-hydroxybutyric acid ............................................................................................................................................................
Heroin ..............................................................................................................................................................................................
Hydromorphinol ................................................................................................................................................................................
Hydroxypethidine .............................................................................................................................................................................
Ibogaine ...........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ....................................................................................................................................................
Marihuana ........................................................................................................................................................................................
Mescaline .........................................................................................................................................................................................
Methaqualone ..................................................................................................................................................................................
Methcathinone .................................................................................................................................................................................
Methyldihydromorphine ....................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ..................................................................................................................................
Noracymethadol ...............................................................................................................................................................................
Norlevorphanol .................................................................................................................................................................................
Normethadone .................................................................................................................................................................................
Normorphine ....................................................................................................................................................................................
Para-fluorofentanyl ...........................................................................................................................................................................
Phenomorphan ................................................................................................................................................................................
Pholcodine .......................................................................................................................................................................................
Psilocybin .........................................................................................................................................................................................
Psilocyn ............................................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................................
Thiofentanyl .....................................................................................................................................................................................
Trimeperidine ...................................................................................................................................................................................
1-Phenylcyclohexylamine ....................................................................................................................................................................
14:35 Aug 23, 2007
Jkt 211001
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
2
2
20
10
22
2
2
7
77
2
12
2
5
2
2
2
2
2
2
2
3
2
2
5
8
2
2
2
2
2
2
2
8
3
302
2
50
2,549,000
3
23,600,000
5
3,000
2
1
61
4,500,000
2
10
4
2
310
7
2
2
2
52
2
16
2
2
2
7
7
312,500
2
2
Final revised
2007 quotas
(grams)
Basic class—Schedule II
VerDate Aug<31>2005
48687
E:\FR\FM\24AUN1.SGM
24AUN1
2
48688
Federal Register / Vol. 72, No. 164 / Friday, August 24, 2007 / Notices
Final revised
2007 quotas
(grams)
Basic class—Schedule II
yshivers on PROD1PC66 with NOTICES
Alfentanil ..............................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
Amobarbital ..........................................................................................................................................................................................
Amphetamine (for sale) .......................................................................................................................................................................
Amphetamine (for conversion) ............................................................................................................................................................
Cocaine ................................................................................................................................................................................................
Codeine (for sale) ................................................................................................................................................................................
Codeine (for conversion) .....................................................................................................................................................................
Dextropropoxyphene ............................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................................
Diphenoxylate ......................................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................................
Glutethimide .........................................................................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................................................................
Hydrocodone (for conversion) .............................................................................................................................................................
Hydromorphone ...................................................................................................................................................................................
Isomethadone ......................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................
Levomethorphan ..................................................................................................................................................................................
Levorphanol .........................................................................................................................................................................................
Lisdexamfetamine ................................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Metazocine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
Methylphenidate ...................................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
Nabilone ...............................................................................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
Opium ..................................................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxymorphone ......................................................................................................................................................................................
Oxymorphone (for conversion) ............................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
The Deputy Administrator further
orders that the aggregate production
quotas for all other schedules I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 shall be zero.
The Office of Management and Budget
has determined that notices of aggregate
production quotas are not subject to
centralized review under Executive
Order 12866.
This action does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
action does not have federalism
implications warranting the application
of Executive Order 13132.
VerDate Aug<31>2005
14:35 Aug 23, 2007
Jkt 211001
The Deputy Administrator hereby
certifies that this action will have no
significant impact upon small entities
whose interests must be considered
under the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. The establishment of
aggregate production quotas for
schedules I and II controlled substances
is mandated by law and by international
treaty obligations. The quotas are
necessary to provide for the estimated
medical, scientific, research and
industrial needs of the United States, for
export requirements and the
establishment and maintenance of
reserve stocks. While aggregate
production quotas are of primary
importance to large manufacturers, their
impact upon small entities is neither
negative nor beneficial. Accordingly, the
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
5,200
2
3
17,000,000
5,000,000
286,000
39,605,000
59,000,000
120,000,000
2,435,000
828,000
83,000
2
1,428,000
2
46,000,000
1,500,000
3,300,000
2
6
5
6,000
6,200,000
9,753,000
1
25,000,000
26,000,000
3,130,000
50,000,000
35,000,000
110,774,000
3,002
1,002
11,000,000
1,400,000
70,000,000
3,100,000
1,800,000
15,300,000
35,200,000
2,021
2
2
3,000
2
10,300
126,000,000
Deputy Administrator has determined
that this action does not require a
regulatory flexibility analysis.
This action meets the applicable
standards set forth in sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by state, local, and tribal
governments, in the aggregate or by the
private sector, of $120,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by section 804 of the Small
Business Regulatory Enforcement
E:\FR\FM\24AUN1.SGM
24AUN1
Federal Register / Vol. 72, No. 164 / Friday, August 24, 2007 / Notices
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
companies to compete with foreignbased companies in domestic and
export markets.
Dated: August 15, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–16730 Filed 8–23–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Agency Information Collection
Activities: Revision and Extension of a
Currently Approved Information
Collection; Comment Request
60-day notice of information
collection under review: Application for
Permanent Employment Certification;
Form ETA–9089, OMB Control No.
1205–0451.
yshivers on PROD1PC66 with NOTICES
ACTION:
SUMMARY: The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden, is
conducting a pre-clearance consultation
to provide the general public and
Federal agencies with an opportunity to
comment on proposed and/or
continuing collections of information in
accordance with the Paperwork
Reduction Act of 1995 (PRA95) [44
U.S.C. 3506(c)(2)(A)]. This consultation
is undertaken to ensure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. Currently, the
Employment and Training
Administration is soliciting comments
concerning Form ETA 9089 Application
for Permanent Employment
Certification. A copy of the proposed
information collection request (ICR) can
be obtained by contacting the office
listed below in the addressee section of
this notice or at this Web site: https://
www.doleta.gov/OMBCN/
OMBControlNumber.cfm.
Written comments must be
submitted to the office listed in the
addressee section below on or before
October 23, 2007.
DATES:
VerDate Aug<31>2005
14:35 Aug 23, 2007
Jkt 211001
William L. Carlson,
Administrator, Office of Foreign Labor
Certification, U.S. Department of Labor,
Room C4312, 200 Constitution Ave.,
NW., Washington, DC 20210. Phone
(202) 693–3010 (This is not a toll-free
number.), fax (202) 693–2768, or e-mail
at ETA.OFLC.Forms@dol.gov subject
line: Form ETA 9089.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
I. Background
The information collection is required
by sections 203(b)(3) and 212(a)(5)(A) of
the Immigration and Nationality Act
(INA) (8 U.S.C. 1153(b)(3) and
1182(a)(5)(A)). The Department of Labor
(Department) and the Department of
Homeland Security (DHS) have
promulgated regulations to implement
the INA. Specifically for this collection,
Title 20 CFR 656 and Title 8 CFR 204.5
are applicable. The INA mandates the
Secretary of Labor to certify that any
alien seeking to enter the United States
for the purpose of performing skilled or
unskilled labor is not adversely affecting
wages and working conditions of U.S.
workers similarly employed and that
there are not sufficient U.S. workers
able, willing, and qualified to perform
such skilled or unskilled labor. Before
any employer may request any skilled or
unskilled alien labor, it must submit a
request for certification to the Secretary
of Labor containing the elements
prescribed by the INA and the CFR. The
CFR requires employers to document
their recruitment efforts and
substantiate the reasons no U.S. workers
were hired.
II. Review Focus
The Department of Labor is
particularly interested in comments
which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
48689
III. Current Actions
In order to meet its statutory
responsibilities under the INA, the
Department needs to extend an existing
collection of information pertaining to
employers seeking to apply for
permanent employment certification to
allow them to bring foreign labor to the
United States on a permanent basis.
Extensive program experience, in
particular since its reengineering in
2005, has demonstrated the need for
further clarification on this information
collection and has shown that changes
to the collection are also necessary.
In the past the respondents have been
for-profit businesses, not-for-profit
institutions, individuals, households,
and farms. On rare occasions the
respondents have been local, state, tribal
governments, or the federal government.
The Secretary of Labor uses the
collected information to determine if
allowing an alien to enter the United
States for the purpose of performing
skilled or unskilled labor will adversely
affect wages and working conditions of
U.S. workers similarly employed and
whether or not there were sufficient
U.S. workers able, willing, and qualified
to perform such skilled or unskilled
labor at the time of the application.
Changes are being proposed to ETA
Form 9089 for two reasons. The first is
to provide more clarity to the user of the
form, thereby obtaining more accurate
information for the Department to assist
in more efficient and effective
adjudication of the requested benefit.
The second is to implement
amendments required by the Final Rule
published in the Federal Register May
17, 2007: Labor Certification for the
Permanent Employment of Aliens in the
United States; Reducing the Incentives
and Opportunities for Fraud and Abuse
and Enhancing Program Integrity.
Type of Review: Revision and
Extension of Currently Approved
Information Collection.
Agency: Employment and Training
Administration.
Title: Application for Permanent
Employment Certification.
OMB Control No.: 1205–0451.
Agency Number(s): Form ETA 9089.
Recordkeeping: On occasion.
Affected Public: Businesses or other
for-profits and not-for-profits,
individuals or households, farms, and
Federal, State, Local or Tribal
Governments.
Total Respondents: 120,000.
Estimated Total Burden Hours:
342,686.
Total Burden Cost (capital/startup): 0.
Total Burden Cost (operating/
maintaining): $2,500,000.
E:\FR\FM\24AUN1.SGM
24AUN1
Agencies
[Federal Register Volume 72, Number 164 (Friday, August 24, 2007)]
[Notices]
[Pages 48686-48689]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16730]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-290F]
Controlled Substances: Final Revised Aggregate Production Quotas
for 2007
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of final aggregate production quotas for 2007.
-----------------------------------------------------------------------
SUMMARY: This notice establishes final 2007 aggregate production quotas
for controlled substances in schedules I and II of the Controlled
Substances Act (CSA). The DEA has taken into consideration comments
received in response to a notice of the proposed revised aggregate
production quotas for 2007 published May 3, 2007 (72 FR 24608).
EFFECTIVE DATE: August 24, 2007.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, PhD, Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires that the Attorney General establish aggregate production
quotas for each basic class of controlled substance listed in schedules
I and II. This responsibility has been delegated to the Administrator
of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated
this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
The 2007 aggregate production quotas represent those quantities of
controlled substances in schedules I and II that may be produced in the
United States in 2007 to provide adequate supplies of each substance
for: the estimated medical, scientific, research and industrial needs
of the United States; lawful export requirements; and the establishment
and maintenance of reserve stocks (21 U.S.C. 826(a) and 21 CFR
1303.11). These quotas do not include imports of controlled substances.
On May 3, 2007, a notice of the proposed revised 2007 aggregate
production quotas for certain controlled substances in schedules I and
II was published in the Federal Register (72 FR 24608). All interested
persons were invited to comment on or object to these proposed
aggregate production quotas on or before May 24, 2007.
Nine companies commented on a total of 31 schedules I and II
controlled substances within the published comment period. Nine
companies proposed that the aggregate production quotas for 14-
hydroxymorphinone, alfentanil, amphetamine (for sale), amphetamine (for
conversion), cocaine, codeine (for conversion), dextropropoxyphene,
dihydromorphine, diphenoxylate, ecgonine, fentanyl, gamma
hydroxybutyric acid, hydrocodone, hydromorphone, lisdexamfetamine,
meperidine, methadone, methadone intermediate, methylphenidate,
morphine, morphine (for conversion), nabilone, noroxymorphone (for
conversion), oxycodone, oxymorphone, oxymorphone (for conversion),
pentobarbital, remifentanil, sufentanil, tetrahydrocannabinols, and
thebaine were insufficient to provide for the estimated medical,
scientific, research, and industrial needs of the United States, for
export requirements and for the establishment and maintenance of
reserve stocks.
The DEA has determined that the compound 14-hydroxymorphinone is a
morphine derivative. The comment received concerning this substance was
therefore, considered as a comment for morphine.
DEA has taken into consideration the above comments along with the
relevant 2006 year-end inventories, initial 2007 manufacturing quotas,
2007 export requirements, actual and projected 2007 sales, research,
product development requirements and additional applications received.
Based on this information, the DEA has adjusted the final 2007
aggregate production quotas for 2,5-dimethoxyamphetamine, alfentanil,
amphetamine (for conversion), gamma-hydroxybutyric acid, hydrocodone,
methylphenidate, oxycodone, oxycodone (for conversion), pentobarbital,
remifentanil, sufentanil and thebaine to meet the legitimate needs of
the United States.
Regarding amphetamine (for sale), cocaine, codeine (for
conversion), dextropropoxyphene, dihydromorphine, diphenoxylate,
ecgonine, fentanyl, hydromorphone, lisdexamfetamine, meperidine,
methadone, methadone intermediate, morphine, morphine (for conversion),
nabilone, noroxymorphone (for conversion), oxymorphone, oxymorphone
(for conversion), and tetrahydrocannabinols the DEA has determined that
the proposed revised 2007 aggregate production quotas are sufficient to
meet the current 2007 estimated medical, scientific, research, and
industrial needs of the United States and to provide for adequate
inventories.
Therefore, under the authority vested in the Attorney General by
section 306 of the CSA (21 U.S.C. 826), and delegated to the
Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy
Administrator, pursuant to 28 CFR 0.104, the Deputy Administrator
hereby orders that the 2007 final aggregate production quotas for the
following controlled substances, expressed in grams of anhydrous acid
or base, be established as follows:
------------------------------------------------------------------------
Final revised
Basic class--Schedule I 2007 quotas
(grams)
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine.............................. 2
2,5-Dimethoxy-4-ethylamphetamine (DOET)............... 2
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7). 10
[[Page 48687]]
3-Methylfentanyl...................................... 2
3-Methylthiofentanyl.................................. 2
3,4-Methylenedioxyamphetamine (MDA)................... 20
3,4-Methylenedioxy-N-ethylamphetamine (MDEA).......... 10
3,4-Methylenedioxymethamphetamine (MDMA).............. 22
3,4,5-Trimethoxyamphetamine........................... 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)................ 2
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)............ 7
4-Methoxyamphetamine.................................. 77
4-Methylaminorex...................................... 2
4-Methyl-2,5-dimethoxyamphetamine (DOM)............... 12
5-Methoxy-3,4-methylenedioxyamphetamine............... 2
5-Methoxy-N,N-diisopropyltryptamine................... 5
Acetyl-alpha-methylfentanyl........................... 2
Acetyldihydrocodeine.................................. 2
Acetylmethadol........................................ 2
Allylprodine.......................................... 2
Alphacetylmethadol.................................... 2
Alpha-ethyltryptamine................................. 2
Alphameprodine........................................ 2
Alphamethadol......................................... 3
Alpha-methylfentanyl.................................. 2
Alpha-methylthiofentanyl.............................. 2
Alpha-methyltryptamine................................ 5
Aminorex.............................................. 8
Benzylmorphine........................................ 2
Betacetylmethadol..................................... 2
Beta-hydroxy-3-methylfentanyl......................... 2
Beta-hydroxyfentanyl.................................. 2
Betameprodine......................................... 2
Betamethadol.......................................... 2
Betaprodine........................................... 2
Bufotenine............................................ 8
Cathinone............................................. 3
Codeine-N-oxide....................................... 302
Diethyltryptamine..................................... 2
Difenoxin............................................. 50
Dihydromorphine....................................... 2,549,000
Dimethyltryptamine.................................... 3
Gamma-hydroxybutyric acid............................. 23,600,000
Heroin................................................ 5
Hydromorphinol........................................ 3,000
Hydroxypethidine...................................... 2
Ibogaine.............................................. 1
Lysergic acid diethylamide (LSD)...................... 61
Marihuana............................................. 4,500,000
Mescaline............................................. 2
Methaqualone.......................................... 10
Methcathinone......................................... 4
Methyldihydromorphine................................. 2
Morphine-N-oxide...................................... 310
N,N-Dimethylamphetamine............................... 7
N-Ethylamphetamine.................................... 2
N-Hydroxy-3,4-methylenedioxyamphetamine............... 2
Noracymethadol........................................ 2
Norlevorphanol........................................ 52
Normethadone.......................................... 2
Normorphine........................................... 16
Para-fluorofentanyl................................... 2
Phenomorphan.......................................... 2
Pholcodine............................................ 2
Psilocybin............................................ 7
Psilocyn.............................................. 7
Tetrahydrocannabinols................................. 312,500
Thiofentanyl.......................................... 2
Trimeperidine......................................... 2
------------------------------------------------------------------------
------------------------------------------------------------------------
Final revised
Basic class--Schedule II 2007 quotas
(grams)
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................. 2
[[Page 48688]]
Alfentanil.............................................. 5,200
Alphaprodine............................................ 2
Amobarbital............................................. 3
Amphetamine (for sale).................................. 17,000,000
Amphetamine (for conversion)............................ 5,000,000
Cocaine................................................. 286,000
Codeine (for sale)...................................... 39,605,000
Codeine (for conversion)................................ 59,000,000
Dextropropoxyphene...................................... 120,000,000
Dihydrocodeine.......................................... 2,435,000
Diphenoxylate........................................... 828,000
Ecgonine................................................ 83,000
Ethylmorphine........................................... 2
Fentanyl................................................ 1,428,000
Glutethimide............................................ 2
Hydrocodone (for sale).................................. 46,000,000
Hydrocodone (for conversion)............................ 1,500,000
Hydromorphone........................................... 3,300,000
Isomethadone............................................ 2
Levo-alphacetylmethadol (LAAM).......................... 6
Levomethorphan.......................................... 5
Levorphanol............................................. 6,000
Lisdexamfetamine........................................ 6,200,000
Meperidine.............................................. 9,753,000
Metazocine.............................................. 1
Methadone (for sale).................................... 25,000,000
Methadone Intermediate.................................. 26,000,000
Methamphetamine......................................... 3,130,000
Methylphenidate......................................... 50,000,000
Morphine (for sale)..................................... 35,000,000
Morphine (for conversion)............................... 110,774,000
Nabilone................................................ 3,002
Noroxymorphone (for sale)............................... 1,002
Noroxymorphone (for conversion)......................... 11,000,000
Opium................................................... 1,400,000
Oxycodone (for sale).................................... 70,000,000
Oxycodone (for conversion).............................. 3,100,000
Oxymorphone............................................. 1,800,000
Oxymorphone (for conversion)............................ 15,300,000
Pentobarbital........................................... 35,200,000
Phencyclidine........................................... 2,021
Phenmetrazine........................................... 2
Racemethorphan.......................................... 2
Remifentanil............................................ 3,000
Secobarbital............................................ 2
Sufentanil.............................................. 10,300
Thebaine................................................ 126,000,000
------------------------------------------------------------------------
The Deputy Administrator further orders that the aggregate
production quotas for all other schedules I and II controlled
substances included in 21 CFR 1308.11 and 1308.12 shall be zero.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866.
This action does not preempt or modify any provision of state law;
nor does it impose enforcement responsibilities on any state; nor does
it diminish the power of any state to enforce its own laws.
Accordingly, this action does not have federalism implications
warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq.
The establishment of aggregate production quotas for schedules I and II
controlled substances is mandated by law and by international treaty
obligations. The quotas are necessary to provide for the estimated
medical, scientific, research and industrial needs of the United
States, for export requirements and the establishment and maintenance
of reserve stocks. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
This action meets the applicable standards set forth in sections
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by state, local, and
tribal governments, in the aggregate or by the private sector, of
$120,000,000 or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under the provisions of the Unfunded Mandates Reform Act of
1995.
This action is not a major rule as defined by section 804 of the
Small Business Regulatory Enforcement
[[Page 48689]]
Fairness Act of 1996. This action will not result in an annual effect
on the economy of $100,000,000 or more; a major increase in costs or
prices; or significant adverse effects on competition, employment,
investment, productivity, innovation, or on the ability of United
States-based companies to compete with foreign-based companies in
domestic and export markets.
Dated: August 15, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7-16730 Filed 8-23-07; 8:45 am]
BILLING CODE 4410-09-P